Investor Presentation

Here is the financial summary: **Financial Highlights:** * Q1 FY26 consolidated total income reached ₹1,051 Cr (+2.4% YoY). Adjusted EBITDA stood at ₹156 Cr (14.8% margin, +208 bps YoY), with Adjusted PAT at ₹65 Cr (6.2% margin, +57 bps YoY). * Cash surplus surged to ₹1,518 Cr (from ₹566 Cr in FY25) following a €100 Mn advance for a European CDMO contract. * CDMO segment accounts for 79.4% of revenue, showing improved gross margins driven by a focus on niche products. **Strategic Initiatives & Growth Drivers:** * Achieved 1,000 DCGI approvals, with 27 secured in Q1 FY26. * Received first EU dossier approval (Rivaroxaban) and filed first Dapagliflozin combination dossier in Switzerland. * EU contract commercial supplies are on track to commence by April 2027. Strong liquidity supports organic and inorganic growth. * Implemented Zero Liquid Discharge (ZLD) across 5 plants. **Business Developments:** * Secured a €100 Mn advance payment for the European CDMO contract. * Received Brazil ANVISA approval for Plant 3 and Russia GMP for Plant 4. * Strengthened senior leadership teams across IT, Finance, and Strategy. **Market Position & Competitive Advantage:** * The company aims to be a leading global CDMO, leveraging its robust R&D pipeline for long-term growth. * Despite overall market volume growth being muted (<0.5%) and continued weakness in API pricing, the company remains well-positioned. **Investor Implications:** * The substantial cash surplus and expanding pipeline of approvals indicate positive growth potential. * Focus on niche products and CDMO leadership could enhance future profitability. * However, the ongoing softness in market volumes and API prices presents an execution risk to monitor.